═══════════════════════════ FOR LARGE PHARMA
═══════════════════════════

GLOBAL PHARMACEUTICAL LEADERS...

Comprehensive Validation for Regulatory Excellence

Your development programs represent $100M–$500M+ investments. When you advance a compound to clinical development, failure is not just expensive—it affects shareholder confidence, pipeline projections, and global competitive positioning.

TITAN™ provides the definitive safety validation layer that complements your existing preclinical strategy, delivering unprecedented datasets that eliminate surprises and build unshakeable regulatory confidence.

Schedule Executive Consultation

Not sure which service tier fits your needs?

[View Service Tiers & Pricing ]

Looking for a different customer segment?

[Biotech Startups] | [Mid-Size Pharma] | [Other Organizations]

THE BIG PHARMA REALITY

FAILURE IS NOT AN OPTION

Maximum Investment Demands Maximum Confidence

Your clinical programs are massive undertakings that shape company strategy and market positioning. By the time you reach IND submission, you've committed enormous resources with high stakeholder expectations for success.

Positively Impacting Large Pharma:

The High-Stakes Environment:

Investment Magnitude: Substantial Investments of $100M–$500M+ required per clinical program.
The Cost of Being Wrong: Phase II/III failures due to unexpected safety issues damage company credibility, affect stock price, and consume regulatory bandwidth.
Industry Reality: 30% of late-stage failures involve safety issues that could have been better characterized preclinically with advanced methodologies.
Strategic Need: Identify "losers" and "winners" early enough to facilitate expedited de-prioritization and redirect budget to more promising assets. De-Risk aggressively to accommodate the fail fast and fail often Go or No-Go decision making needed for maximized ROI and shareholder expectations

Evolving Regulatory Expectations

The FDA and global regulators are moving toward Model-Informed Drug Development. Regulatory leaders now present cutting-edge multi-modal datasets that demonstrate scientific rigor and advanced risk assessment capabilities far beyond standard preclinical packages.

DEFINITIVE VALIDATION
HOW TITAN™ ELEVATES YOUR PROGRAMS
The Ultimate Safety Validation Before Clinical Investment

Move from "standard tox packages" to "definitive multi-modal validation".

The Strategic Solution:

Stage 1: Comprehensive Multi-Modal Validation

Generate the most comprehensive preclinical safety dataset available. Use SPECT/CT + MRI + biomarkers to map onset, peak, and resolution kinetics.
Preemptively Evaluate: Explore candidates and identify programs with unacceptable risk/reward ratios before they reach the clinical stage.
Compare Safety Profiles: Evaluate backup compounds and different therapeutic areas head-to-head to ensure only the most viable assets move forward.
Early Warning System: Detect problematic toxicity patterns before committing to expensive and time-consuming GLP investment.

Stage 2: Regulatory Leadership Positioning

Present safety narratives supported by longitudinal evidence. Build regulatory confidence by demonstrating an advanced understanding of toxicity mechanisms.
Generate 3Rs Compliant Packages: Exceed FDA expectations for animal welfare and scientific rigor while maximizing asset valuation.
Pre-IND Meeting Prep: Arrive at the FDA with preliminary safety packages that anticipate and answer toxicity questions before they are asked.
Asset Valuation Premium: Evaluate potential portfolio acquisitions with "due diligence" clarity. Internally, command higher licensing valuations by presenting comprehensive safety differentiation that competitors cannot match.

What TITAN™ Reveals

Spatial-Temporal Cytotoxic Tissue Damage Maps: Precisely identify where damage occurs, when it starts, and to what extent it impacts systemic health.
Susceptible Population Identification: Assess age, sex, and demographic differences to meet evolving FDA requirements for population-specific safety.
Competitive Clinical Positioning: Use early safety evidence to bring safer candidates deeper into lead optimization. This maximizes ROI and minimizes safety problems discovered later in development when substantial investment has already been allocated.

PORTFOLIO TRANSFORMATION

FROM REACTIVE TROUBLESHOOTING TO PARALLEL INTELLIGENCE

Scientific Leadership Through Advanced Safety Assessment
Moving from "sequential validation" to
"parallel intelligence" transforms your R&D budget from a sunk cost into a strategic lever.

The Strategic Advantages:

Portfolio Optimization: Apply TITAN™ across multiple programs to identify "losers" early, allowing you to redirect budget from doomed programs to assets with validated safety profiles.
Business Development Premium: Whether you are looking to be acquired or are evaluating a potential acquisition, TITAN™ provides the "due diligence" clarity needed to justify premium valuations and secure higher licensing terms.
Scientific Leadership: Present breakthrough safety assessment methodologies at major international conferences (e.g., AACR, ASCO, SOT). Establish your organization as the innovation leader in advanced preclinical characterization.
Long-Term Competitive Moats: Organizations investing in cutting-edge safety assessment build lasting differentiation. Advanced preclinical capabilities become sustainable advantages that competitors using traditional approaches cannot match.

The Business Impact:

Resource Optimization: The cost of screening five programs with TITAN™ is less than the typical cost of one failed Phase I study ($10M–$15M).
Therapeutic Area Leadership: Become the recognized safety leader in your therapeutic areas, attracting top talent, premium partnership opportunities, and regulatory recognition.
Platform Validation: For platform-based approaches (ADCs, cell/gene therapies, etc.), TITAN™ characterizes platform-specific safety profiles regardless of the specific candidate or target. This provides a baseline understanding that serves to inform your entire global development strategy and future pipeline architecture.

RECOMMENDED STRATEGY
THE LARGE PHARMA APPROACH
Comprehensive Validation Designed for Strategic Decision-Making

Most Large Pharma Choose: Comprehensive Tier + Advanced

Add-Ons ($400K–$1M+)

The Comprehensive Tier provides the multi-modal imaging, full histopathology, and board-certified review necessary to maximize asset valuation and inform internal Go/No-Go decisions. This level of data depth is required for high-stakes portfolio reviews and partnership due diligence, providing the rigorous evidence needed to support global regulatory filings and internal safety governance committee reviews.

The Comprehensive Capability Set

Multi-Modal Data: SPECT/CT + MRI + Full Histopathology providing maximum dataset depth for maximum understanding and regulatory and BD credibility.
Full Histopathology Service: H&E, TUNEL, and board-certified pathologist review.
Board-Certified Review: Professional mechanistic toxicity mapping to explain the how and why.
Regulatory-Ready Analysis: Publication-quality documentation and figures for internal stakeholders and external partners and formal IND submissions.
Mechanistic Insights: Spatial-temporal toxicity progression mapping to inform Lead Optimization.
Volume Pricing: Strategic discounts available for multi-program pipeline assessments.
Advanced Imaging: Cardiac MRI and fMRI for deep mechanistic insights into CNS or cardiac-targeted compounds.

Key Performance Deliverables:

Global Submission Ready: Publication-quality documentation and figures for FDA, EMA, and PMDA.
Large Animal Validation: Seamless scaling to Dog and NHP studies for maximum human translation and biologics validation.
Demographic Sensitivity: Age and sex comparison matrices to meet the evolving FDA "Diversity Action Plan" requirements.
Specialized Mechanistic Depth: Integration of advanced and complementary imaging methods such as Cardiac MRI or fMRI to resolve specific safety concerns such as CNS or cardiovascular-targeted assets.

VALUE PROJECTION MODELS

PIPELINE TRANSFORMATION ARCHITECTURE

Theoretical Impact Benchmarks:

Lead Optimization to IND

The following represent theoretical strategic models based on TITAN™ capabilities and typical industry cost-averages. These benchmarks serve as a framework for projecting internal ROI and regulatory impact.

MODEL 1: Lead Optimization & Portfolio Filtering (Theoretical)

The Scenario: A CNS program with 12 leads and a budget for only two GLP commitments. Sequential testing risks patent-life decay and "silent" toxicities entering the clinic.

The Strategic Outcome:

Identified Winners: 2 "Super-Candidates" identified with 10x safety margins over competitive benchmarks, providing a clear path for Best-in-Class labeling.
Risk Mitigation: Parallel TITAN™ screening identified "silent" signals in 7 leads that traditional pathology would have missed until Phase I.
Value Creation: Established a target-independent safety profile for the platform vehicle, validating the "delivery backbone" for future pipeline assets.
Timeline Compression: Estimated 18-month acceleration of GLP transition, significantly increasing program NPV.

Projected Financial Impact:

Cost Avoidance: ~$12M in avoided synthesis, formulation, and preliminary tox spend on the 7 failing assets.
Resource Optimization: Redirected $45M in downstream development capital from low-probability leads to the validated high-margin winners.
Timeline Acceleration: Accelerated IND submission by 1.5 years, gaining an estimated $250M in Net Present Value (NPV) through extended patent exclusivity.
Projected ROI: A 1,800% return on the TITAN™ investment based on the total reduction in the cost-per-approved-molecule.

The Financial Impact: $12M in direct savings, $45M in redirected capital, and a 1.5-year head start on market entry.

THE BOTTOM LINE:
STRATEGIC DE-RISKING
TITAN™ provides the "Insurance Policy" for $100M+ clinical assets. By moving definitive safety intelligence upstream, leadership can quantify the value of aggressive portfolio filtering. This isn't just about saving R&D spend; it's about establishing a scientific moat that maximizes asset valuation and ensures your capital is deployed only on candidates with the highest statistical probability of success.

MODEL 2: Platform Validation & Partnership Premium (Theoretical)

The Scenario: A Top-10 pharmaceutical leader is managing a $300M+ CAR-T platform investment. To justify continued internal funding and future clinical expansion, they must prove their delivery vehicle is differentiated from competing assets plagued by "hidden" neurotoxicity and cardiotoxicity failures.

The Strategic Outcome:

Identified Winners: Confirmed a predictable, target-independent safety profile for the "delivery backbone," validating the platform for 4 additional internal assets.
Risk Mitigation: Identified subtle cardiac biomarker signatures 48 hours before clinical symptoms, allowing for the immediate termination of high-risk assets before GLP commitment.
Value Creation: Generated a 3Rs-compliant, publication-quality dataset that earned favorable FDA feedback during Pre-IND discussions for its unprecedented depth of characterization.
Timeline Compression: Accelerated the lead asset to Phase I entry by 14 months by resolving mechanistic safety questions in the preclinical phase rather than the clinic.

Projected Financial Impact:

Business Development Premium: Secured continued Board-level funding for the entire platform (Theoretical baseline: $400M+ internal allocation) directly attributed to the depth of the safety due diligence package.
Resource Optimization: Prevented the loss of $45M in "sunk" manufacturing and clinical trial costs by eliminating toxic assets before they reached the clinic.
Timeline Acceleration: Accelerated the achievement of the first clinical milestone, gaining a "First-in-Class" competitive advantage worth an estimated $500M in lifetime peak sales.
Projected ROI: A 2,200% return on the TITAN™ investment based on the massive increase in upfront partnership capital and avoided clinical failure costs.

The Financial Impact: $400M in upfront partnership capital, $45M in avoided clinical waste, and a 14-month acceleration to market.

THE BOTTOM LINE:
MAXIMIZING ASSET VALUATION
TITAN™ is the ultimate "Due Diligence" weapon for high-stakes assets. By providing an unprecedented level of safety characterization, you don't just de-risk your molecule; you ensure your most promising assets receive the capital and regulatory priority they deserve. This ensures your organization captures the full market value of its innovation while building an unshakeable reputation for scientific excellence.

ENTERPRISE INTEGRATION
SEAMLESS GOVERNANCE & SCIENTIFIC ALIGNMENT

Custom Solutions Built for the Complexity of Global Drug Development:

Large Pharma operates within a complex ecosystem of internal committees, global regulators, and competing priorities. TITAN™ is engineered to bridge these gaps, providing a unified "Safety Language" that accelerates consensus and reduces internal friction.

Internal Safety Governance & Review Board Support:

For global organizations, data must be portable across diverse regulatory landscapes.

Consensus Building: We provide the mechanistic data and 3D visualizations needed to satisfy Internal Safety Governance Committees, moving assets from "Review" to "Greenlight" faster.
Conflict Resolution: When traditional histopathology and clinical chemistry provide conflicting signals, our multi-modal imaging acts as the "tie-breaker," providing spatial-temporal clarity.
Executive Summaries: We provide "Board-Ready" summaries that translate complex toxicological findings into clear, actionable Go/No-Go recommendations for non-scientist stakeholders.

Global Regulatory & Multi-Region Filing Alignment:

Moving an asset through internal milestones requires defensible, high-resolution data that survives intense scrutiny.

Unified Narrative: Our data packages are structured for simultaneous utility across the FDA, EMA, and PMDA, ensuring a unified global safety narrative that prevents contradictory questions from different regions.
Diversity Action Plan Compliance: Explicitly satisfy new FDA mandates with integrated Age/Sex comparison matrices, ensuring your safety package reflects the demographic diversity required for modern clinical entry.
3Rs Stewardship: Align with corporate ESG and animal welfare goals by utilizing our non-invasive, longitudinal approach to maximize data points per animal.

Technical Data Interoperability:

We ensure that the data we generate is as mobile as the teams using it.

Knowledge Management Integration: High-fidelity datasets are provided in formats that integrate directly into your internal Knowledge Management Systems (KMS) and Electronic Lab Notebooks (ELN).
eCTD Ready: All figures, tables, and reports are formatted for immediate inclusion in electronic Common Technical Document (eCTD) submissions for IND/NDA filings.
Cloud-Based Collaboration: Secure, encrypted access to study reports, analyzed imaging results, figures, and sponsor deliverables enables your internal teams to review findings and collaborate efficiently across functions and locations.

Cross-Functional Strategic Utility:

One TITAN™ study creates value across the entire organization, reducing the need for redundant, fragmented testing.

Toxicology: Provides definitive mechanistic mapping of liabilities.
Clinical Pharmacology: Informs starting dose and escalation logic through refined NOAEL (No-Observed-Adverse-Effect-Level) calculations.
Business Development & M&A: Provides the rigorous "due diligence" evidence needed to defend asset valuation during partnership or acquisition talks.

"TITAN™ provides the Definitive Integrated Narrative for asset safety." By delivering a multi-modal, longitudinal dataset, we provide the scientific evidence needed to reconcile conflicting signals often found in fragmented traditional studies. This leads to streamlined consensus among internal stakeholders and a more transparent, data-driven posture before global regulators.

READY TO ACHIEVE REGULATORY EXCELLENCE?

Unparalleled Intelligence And Definitive Safety Characterization for Your Critical Assets